AFMDQ.US Affimed N.V.
- Market cap
- USD 1.64K
- P/E
- -
- P/B
- 0.00x
- ROE
- -352.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2024.
Is AFMDQ.US undervalued?
Graham numberThe Graham number of Affimed N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Affimed N.V. fundamental analysis
No fundamental analysis for Affimed N.V. yet.
Affimed N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding in…
Full company profileAffimed N.V. financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Affimed N.V. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 40.4M | 41.4M | 8.28M | 620K |
| Operating Income | -65.0M | -89.0M | -111M | -57.2M |
| EBITDA | -55.5M | -81.5M | -102M | - |
| Net Income | -57.5M | -86.0M | -106M | -60.6M |
| EPS | -4.66 | -5.76 | -7.06 | -3.69 |
| Balance Sheet | ||||
| Total Assets | 225M | 201M | 97.2M | 40.0M |
| Total Liabilities | 89.2M | 47.6M | 39.4M | 22.8M |
| Shareholders' Equity | 136M | 153M | 57.8M | 17.2M |
| Cash & Short-term Investments | 198M | 190M | 38.5M | 7.41M |
| Cash Flow | ||||
| Operating Cash Flow | -86.6M | -105M | -110M | - |
| Capital Expenditure | 3.85M | 696K | 3.73M | 6.67K |
| Free Cash Flow | -90.4M | -106M | -114M | - |
| Ratios | ||||
| ROE | -42.3% | -56.2% | -183.3% | -352.2% |
| ROA | -25.6% | -42.9% | -109.0% | -151.5% |
| Net Profit Margin | -142.5% | -208.0% | -1,280.2% | -9,767.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Affimed N.V. dividends
Affimed N.V. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:10 on Mar 11, 2024.
Who owns Affimed N.V.
Ownership data of Affimed N.V. is not available yet.
Affimed N.V. company profile
- Company name
- Affimed N.V.
- Ticker
- AFMDQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Fiscal year end
- December
- Address
- Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165
- Phone
- 49 621 560030
- Website
- affimed.com
About Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Affimed N.V. management
6- Dr. Wolfgang Fischer Ph.D.MD, COO, Chief Strategy Officer & Member of Management Board · born 1964
- Dr. Andreas Harstrick M.D.Chief Medical Officer & Member of Management Board · born 1961
- Prof. Melvyn LittleFounder & Consultant
- Mr. Michael WolfHead of Finance & Administration · born 1967
- Mr. Alexander FudukidisHead of Investor Relations & Director of Investor Relations
- Mary Beth SandinVice President of Marketing & Communications